Firsekibart in Reducing High-Sensitivity C-reactive Protein Levels of Gout

2025-11-07T16:01:17+08:00

Background: Gout remains a challenging condition with rising global prevalence. The IL-1β drives disease pathogenesis, and high-sensitivity C-reactive protein (hsCRP) correlates with gout activity. Firsekibart, a novel fully human anti-IL-1β monoclonal antibody, has proven its efficacy on gout, while the data on reducing hsCRP remains limited. Methods: This multicenter, randomized, double-blind phase III trial compared Firsekibart (200 mg subcutaneous) with compound betamethasone (7 mg intramuscular) in acute gout patients who were contraindicated to, intolerant of, or unresponsive to NSAIDs and/or colchicine. Serum hsCRP levels were measured at 72 hours, 7 days post-dose, and 4 weeks post-dose. Results: Both groups achieved comparable hsCRP reduction at 72 hours (Firsekibart: −14.68 mg/L [95% CI: −15.75, −13.61] vs. compound betamethasone: −14.58 mg/L [−15.66, −13.50]; P=0.898). Firsekibart demonstrated better sustained suppression at 7 days post-dose (−18.63 vs. −9.28 mg/L, P<0.001) and 4 weeks (−18.37 vs. −12.65 mg/L, P<0.0001). Conclusion: Compared with compound betamethasone, Firsekibart showed a longer-lasting anti-inflammatory effect on gout patients. This result may provide significant clinical value in the management of gout and its associated complications.

International Journal of General Practice Nursing

Firsekibart in Reducing High-Sensitivity C-reactive Protein Levels of Gout